EL7.AI
StocksMedium•4 August 2026•
1 min read

Galectin Therapeutics Eliminates Debt via $105.8M Equity Conversion

Key Facts

1Chairman Richard E. Uihlein converted $105.8 million in outstanding notes into common stock.
2The transaction eliminates the company's debt, increases market capitalization, and strengthens the balance sheet.

In a move reflecting strategic balance sheet management within the biotech sector, Galectin Therapeutics has announced a significant debt-to-equity swap. Chairman Richard E. Uihlein converted $105.8 million in outstanding notes from five line of credit facilities into common stock. According to reports, this transaction is designed to eliminate the company's debt obligations and significantly strengthen its financial position.

The conversion effectively increases the company's market capitalization while removing long-term liabilities from the books. By exchanging principal and accrued interest for common shares, the company gains financial flexibility without requiring cash outflows for debt servicing. This corporate action transforms the balance sheet by replacing debt with equity capital, a fundamental shift in its capital structure.

Looking ahead, the company intends to file its Phase 3 protocol for belapectin in Q3 2026, serving as a critical upcoming catalyst for shareholders. Market participants should also monitor broader US economic data in the coming week for shifts in sector sentiment.